Speakers and attendees explored the contours of an industry sector in the throes of regulatory and technological change at the 26th annual Pharmaceutical and Medical Device Ethics and Compliance Congress event in Washington, DC, last week. Discussion unfolded while the federal government was shut down.
Some of the most interesting